Study by Cleveland Clinic shows weight loss drug cuts risk of heart attack by 20% [YZ30Bf4YA]

Study by Cleveland Clinic shows weight loss drug cuts risk of heart attack by 20% [YZ30Bf4YA]

Cleveland Clinic cardiologist, Michael Lincoff, MD made a big announcement over the weekend at an American Heart Association event. The study is big news, but may not be a big surprise. Results from the “SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes” trial were presented today during a late-breaking science session at the American Heart Association’s Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine. In the SELECT trial, which ran from Oct. 2018 through June 2023, researchers enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index of 27 or greater but no history of diabetes. Over 17,000 patients in 41 countries who had previously experienced a heart attack, stroke, and/or had peripheral artery disease were enrolled and followed for an average of 40 months. They were randomly assigned to receive once-weekly injections of semaglutide 2.4 mg or placebo. Semaglutide is the main ingredient in Wegovy, which is FDA-approved for weight loss, and Ozempic which is being used off label, but is mainly meant for those with Type 2 diabetes, The study found those using the drug lost 9.4% of their body weight and experienced improvements in a number of other risk factors for cardiovascular disease, compared to those who received a placebo. But, they also found semaglutide reduced cardiovascular events by 20%. "We hope and anticipate that the FDA, on the basis of this data, will expand that indication for cardiovascular protection, just as they did for diabetes with this drug. If that's the case, then this takes on a new urgency and it becomes more of a standard of care for this group of patients," said Michael Lincoff, M.D., SELECT’s lead author and vice chair for research in Cleveland Clinic’s Department of Cardiovascular Medicine. While the weight loss effects of semaglutide appear to occur primarily through appetite suppression, they found the drug has other actions which may reduce cardiovascular risk, including improvements in glucose levels, decreases in blood pressure and cholesterol levels and reductions in inflammation, and beneficial effects on heart muscle and blood vessels. That's on top of whether the patients were already taking medications for the other conditions. Read: https://www.wkyc.com/article/news/health/cleveland-clinic-doctor-study-weight-loss-drug-cuts-heart-attack-risk-by-20-percent/95-b64fa598-4a7d-413c-9945-5c7357e3da5e -- At 3News, we’re not here to tell you the news, we’re here to share the stories that you say matter most to you. Share your ideas, thoughts, concerns and engage in conversations about the communities in which we all call home. Follow 3News on Social: Facebook: https://www.facebook.com/wkyc.channel3/   Twitter: https://twitter.com/wkyc   Instagram: https://www.instagram.com/wkyc3/   Visit our site: https://www.wkyc.com/ And be sure to download our app here: https://wkyc.com/app

Related Videos :

• How to Make Chicken Bone Broth #recipe #bonebroth #collagen [2UGcv36FD]
• Dietitian explains how to build a balanced healthy meal (portion plate model) #shorts [DdJonPYGr]
• My hack for eating liver [GMq6P1cbD]
• Zendaya Workout And Diet #short [NhVT1UJxZ]
• ↓ 5 Important & Clinically Proven Reasons You Should NOT Take Statin Drugs - by Dr Sam Robbins [S0LJoVy9c]